NIH Clinical Center: Search the Studies

Search the Studies

9 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.

Protocol Number	Title	Protocol Status	Min-Max Age	Institute	Keywords
001715-C	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associ	Recruitment has not started	12-120 Years	NCI	Paraganglioma
001547-C	A First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas	Participants currently recruited/enrolled	18-120 Years	NCI	Paraganglioma
000491-C	Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)	Participants currently recruited/enrolled	18-125 Years	NCI	Paraganglioma
000305-C	Exploratory Phase II Study of LAnreotide in Unresectable or Metastatic Pheochromocytoma / PARAganglioma	No longer recruiting/follow-up only	18-125 Years	NCI	Paraganglioma
000303-C	A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide Vs. Temozolomide and Olaparib For Advanced Pheochromocytoma And Paraganglioma	Participants currently recruited/enrolled	18-125 Years	NCI	Paraganglioma
19-C-0016	Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors	Participants currently recruited/enrolled	0-125 Years	NCI	Paraganglioma
17-C-0087	Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma	Participants currently recruited/enrolled	18-125 Years	NCI	Paraganglioma
14-C-0001	Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma	Completed Study; data analyses ongoing	18-125 Years	NCI	Paraganglioma
00-CH-0093	Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma	Participants currently recruited/enrolled	3-120 Years	NICHD	Paraganglioma